Sixteen of the 143 patients from group 2, in whom stool examination for microsporidian spores and other pathogens was negative, were examined more extensively. Small bowel biopsies were performed either shortly after (eight patients), or before (eight patients) faecal examination with Uvitex 2B. These specimens were examined "blind" by light microscopy for the presence of microsporidia.
The results from this group were used to assess the specificity of the new method.
EVALUATION OF DRUG TREATMENT
Parasitological and clinical response to treatment with paromomycin and albendazole were evaluated in two patients with AIDS for each drug. The patients experienced persistent diarrhoea; biopsy confirmed microsporidiosis was the only recognised microbial cause. Faecal samples were obtained daily and examined with the Uvitex 2B method.
PREPARATION OF SPECIMENS FROM PATIENTS
Fresh faeces (0-5-1 g) were homogenised in 8 ml distilled water and filtered through a 300 ,um pore mesh sieve. D) . The active substance of Uvitex 2B has a X light chain of 355 nm. Uvitex 2B stained faecal smears were stored at room temperature in the dark and re-examined after six and 10 months. The average number of mature spores in five fields/slide (x 1250) was estimated.
To examine the staining properties of Uvitex 2B, smears of E cuniculi obtained from In faecal samples two different microsporidia, confirmed by electron microscopy as E bieneusi and a species of Encephalitozoon, were recognised after staining with Uvitex 2B. The same staining properties-namely bright white fluorescence or reddish brownas observed with the cultured E cuniculi, were exhibited respectively by mature and immature stages of both species. In the faecal smears, however, the immature stages greatly outnumbered the mature spores.
The shape and size of mature spores of E bieneusi (broadly oval, about 1 6 x 1 0 ,im) showed little variation (fig 1) , but the larger spores of Encephalitozoon varied considerably, both in shape and size, being broad and rodlike or kidney shaped, and measuring 2-5-3-3 x 1 3-2 1 ,um. Mature spores and immature developmental stages of Encephalitozoon sp were also seen in urine samples, nasal discharge, maxillary sinus aspirate, and sputum. A morphological characteristic, always present in a proportion of the mature spores of E bieneusi, and (less frequently) in those of Encephalitozoon sp, was a concave inner stripe and shadow. This characteristic was used throughout the study as an important criterion for identification of microsporidian spores. The inner stripe and shadow were not observed in mature spores of E cuniculi derived from culture supematant fluids.
The background was dark brown or black and discrimination between microsporidian spores and fluorescing structures such as yeasts and fungi was possible on the basis of clearly visible differences in size and morphology. Only small fungal spores showed some resemblance to E bieneusi and Encephalitozoon sp spores, but they were more rod-like and the concave inner stripe and shadow were always absent.
The time needed to read the slides varied from 30 seconds to 2 minutes; to exclude microsporidia infection a 3 minute search was sufficient.
Fixation with ethanol 70% or heating of faecal suspensions to 56°C for 30 minutes did not alter the staining properties of mature spores, but fixation with formalin reduced considerably the intensity of fluorescence of mature spores.
Storage of Uvitex 2B stained smears at room temperature in the dark for six months did not influence fluorescence of mature spores but a slight decrease of intensity was observed after 10 months.
Electron microscopic examination of Encephalitozoon infections in small intestinal biopsy specimens showed all developmental stages other than sporoplasms (fig 2) . In patients with E bieneusi infection confirmation was obtained by light microscopic examination of duodenal biopsy specimens in six cases and by electron microscopic examination of faecal samples from the remaining five cases. In one patient with low numbers of E bieneusi spores in faeces, confirmed by electron microscopy, microsporidia were not detected in biopsy specimens either by light microscopic or electron microscopy. In two other patients, with numerous spores in the stool, extensive light microscopic examination of duodenal biopsy smears was required before any infected cell was detected.
Biopsy specimens for electron microscopy examination were available from four of the five patients in whom Encephalitozoon had been found in the faeces with Uvitex 2B; Encephalitozoon infection was confirmed in three (table). In the fourth patient no microsporidia were detected in biopsy specimens even after prolonged examination by both light microscopic and electron microscopy (case 4). The CD4 + counts in the five patients with Encephalitozoon sp infection ranged between 0 01 and 0a 14 x 109/1.
Extraintestinal infection-Urine samples were examined from four of the five patients in whom Encephalitozoon sp had been found as an intestinal infection. In three of them spores and immature stages characteristics of Encephalitozoon sp were detected with Uvitex 2B; electron microscopic confirmation was obtained in two (table). Parasites were located both in extracellular as well as in intracellular positions. The morphology of infected epithelial cells by light microscopy suggested that they had originated from the lower urinary tract. There was no clinical or laboratory evidence for the existence of urinary tract disease. Bacterial cultures from urme were negative.
In two patients with an Encephalitozoon infection (cases 2 and 4) spores were also detected in maxillary sinus aspirate, nasal discharge, and sputum. Ultrastructurally, the mature spores and immature developmental stages observed seemed to be identical with those present in duodenal biopsy specimens.
Group 3
In this group of 16 patients with diarrhoea light microscopy of small intestinal biopsy specimens did not provide evidence of microsporidiosis in any of the patients. A total of 55 stool samples (two to 10 per patient) were examined with negative results (fig 3) .
EVALUATION OF DRUG TREATMENT
Two patients with intestinal E bieneusi infection as the sole known cause of their chronic diarrhoea were treated with oral paromomycin 500 mg three times a day for 12 days. Both patients experienced a decrease in diarrhoeal symptoms, but spores were detected in daily stool samples throughout the treatment period without obvious alteration in the shedding pattern of the spores.
One patient with E bieneusi-associated chronic diarrhoea was treated with oral albendazole 400 mg twice a day for 15 days. This did not result in any changes, either in diarrhoeal signs and symptoms, or in shedding of spores in faeces. Another patient with chronic diarrhoea and biopsy confirmed Encephalitozoon infection of the small intestine with massive spore excretion in the stool received oral albendazole 400 mg twice a day. His diarrhoea lessened in a few days and fully disappeared after three weeks. Spore excretion stopped completely after six days of treatment and the stool remained negative for two months. A duodenal biopsy specimen taken after two months treatment was free of parasites. After 10 weeks, in spite of continued albendazole treatment, diarrhoea recurred and stool examination at 16 weeks contained Encephalitozoon spores again, confirming the clinical relapse.
Discussion
The diagnosis of E bieneusi intestinal microsporidiosis has, until recently, depended on invasive endoscopic procedures.2A13 Noninvasive means for diagnosis became feasible after spores had been recognised in faeces. '2-14 Unfortunately, Giemsa stained faecal preparations require experienced interpretation. Although a recently described chromotrope based staining technique'4 may overcome these restrictions to some extent, the lengthy (2 hours) and laborious staining procedure makes it unsuitable for routine use. The Uvitex 2B method is a considerable advance on previous methods for the diagnosis of microsporidial infections because of its simplicity and the brilliant white fluorescence which facilitates rapid recognition of spores. The staining procedure takes less than 15 minutes to perform, and the time to read the slides reliably is only of the order of minutes. The staining properties are not reduced by the use of ethanol 70% or heating to 56°C for 30 minutes. Therefore, these methods for disinfection of the specimens can be used before they are processed further in the laboratory.
As Uvitex 2B binds to chitin, it is not strictly specific for microsporidia. 14 The microsporidian spores, however, can easily be differentiated by morphological characteristics from other chitin-containing microorganisms.
A valuable feature of the Uvitex 2B method is that it distinguishes between mature chitin-containing spores and noninfective immature spores of both E bieneusi and Encephalitozoon sp. Mature spores of E cuniculi were abundantly present in supernatant fluid from in vitro cultures. In contrast, immature spores of E bieneusi and Encephalitozoon greatly outnumbered mature spores in faeces. This suggests that the lifespan of small intestinal epithelial cells in patients with microsporidiosis is too short for complete development of most of the microsporidia. The concave inner stripe and shadow observed in a large part of the mature spores probably represents a partly collapsed inner spore wall resulting from discharge of the spore contents into the environment.
In all patients with intestinal microsporidiosis, spores were detected with the Uvitex 2B method in all faecal specimens, irrespective of day to day variation in spore shedding and faeces consistency. This is in contrast with observations by Weber et al, who, using the chromotrope-based staining method in two patients with intestinal microsporidiosis, found only five of 25 faecal samples to be positive. '2 Furthermore, some studies suggest a higher sensitivity of Uvitex 2B compared with small intestinal biopsy for diagnosis of intestinal microsporidiosis. In two patients stool examination with the Uvitex 2B method revealed microsporidia (confirmed as E bieneusi and Encephalitozoon sp by electron microscopy of stool and urine sediment, respectively), while duodenal biopsy specimens obtained subsequently were negative by both light microscopy and electron microscopy. In two other patients with numerous spores of E bieneusi in their stools parasites could be found in biopsy specimens only after a prolonged search at light microscopy.
In previous studies with HIV seropositive patients with chronic diarrhoea not explained by other intestinal pathogens, microsporidiosis has ranged from 20 to 30%.2A The prevalence of 11 % (E bieneusi and Encephalitozoon sp combined) found in our study reflects the prevalence of intestinal microsporidiosis in unselected HIV positive patients presenting with diarrhoea.
Until now small intestinal infection with E bieneusi has been the predominant type of microsporidiosis in HIV seropositive individuals. Our staining technique also led to the recognition of small intestinal infection with another genus of microsporidia, which could be distinguished from E bieneusi on the basis of differences in size and shape, and which was ultrastructurally similar to Encephalitozoon.
Serological surveys suggest that antibodies to E cuniculi are relatively common among certain human populations, with rates up to 20% in HIV seropositive individuals.'5 The identification of Encephalitozoon sp in five of the 16 (31%) patients with intestinal microsporidiosis indicates the potential importance of this genus as a cause of chronic diarrhoea in HIV positive subjects. As has been reported for E bieneusi in this study and others,4 12 infections with Encephalitozoon sp were found only in patients with greatly reduced CD4 + lymphocyte numbers.
Whether the tendency of the Encephalitozoon sp to disseminate beyond the gut will result in increased recognition of new clinical syndromes remains to be elucidated. A recent study suggests that Encephalitozoon-like micro-organisms can cause renal pathology in patients with AIDS. 16 The presence of Encephalitozoon spores in sputum as observed in two patients in our study does not prove pulmonary infection by microsporidia as postnasal drip may be mixed with the sputum.
Currently, no proved effective treatment for human microsporidial infections exists. In HIV seropositive patients with E bieneusi intestinal infection clinical improvement of diarrhoeal signs and symptoms has been reported in uncontrolled studies with a small number of patients treated with metronidazole4 or albendazole."7 Neither drug eradicated the parasites from the small intestine, although ultrastructural changes in E bieneusi in biopsy specimens following albendazole treatment have been reported.'9 Paromomycin, an aminoglycoside which shows minimal absorption after oral administration, has recently shown promise for the treatment of cryptosporidial diarrhoea in HIV seropositive patients. 8 In the patients with microsporidiosis due to E bieneusi who were treated with paromomycin or albendazole, no changes in the shedding pattern of spores in stools were seen; although some clinical improvement was observed with paromomycin. This effect could be the result of changes in the intestinal flora by the drug, leading to reduction of intraluminal digestion of malabsorbed nutrients and thus stool volume. An effect of paromomycin on another unrecognised pathogen also cannot be excluded.
In contrast, in the patient with Encephalitozoon infection treatment with albendazole led to clinical improvement as well as cessation of spore shedding in the stool. Recently, we made a similar observation in another patient with Encephalitozoon infection (case 4), with complete cessation of spore shedding in faeces and also in urine and sinus discharge. These findings suggest that albendazole may well exert a different effect on Encephalitozoon and E bieneusi in vivo.
Our new fast and easy staining technique with Uvitex 2B will bring the diagnosis of microsporidial infections within the range of routine practice. Furthermore, it may facilitate research regarding epidemiology, pathogenesis, and treatment of microsporidiosis.
